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Abstract
Background: The aim of this analysis was to investigate the potential impact of Ki67 assay in a series of patients
affected by early stage invasive lobular carcinoma (ILC) undergone surgery.
Methods: Clinical-pathological data were correlated with disease-free and overall survival (DFS/OS). The maximally
selected Log-Rank statistics analysis was applied to the Ki67 continuous variable to estimate appropriate cut-offs.
The Subpopulation Treatment Effect Pattern Plot (STEPP) analysis was performed to assess the interaction between
‘pure’ or ‘mixed’ histology ILC and Ki67.
Results: At a median follow-up of 67 months, 10-years DFS and OS of 405 patients were 67.8 and 79.8 %,
respectively. Standardized Log-Rank statistics identified 2 optimal cut-offs (6 and 21 %); 10-years DFS and OS were
75.1, 66.5, and 30.2 % (p = 0.01) and 84.3, 76.4 and 59 % (p = 0.003), for patients with a Ki67 < 6 %, between 6 and
21 %, and >21 %, respectively. Ki67 and lymph-node status were independent predictor for longer DFS and OS at
the multivariate analysis, with radiotherapy (for DFS) and age (for OS). Ki67 highly replicated at the internal cross-
validation analysis (DFS 85 %, OS 100 %). The STEPP analysis showed that DFS rate decreases as Ki67 increases and
those patients with ‘pure’ ILC performed worse than ‘mixed’ histology.
Conclusions: Despite the retrospective and exploratory nature of the study, Ki67 was able to significantly
discriminate the prognosis of patients with ILC, and the effect was more pronounced for patients with ‘pure’ ILC.
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Background
Invasive lobular carcinoma (ILC, 5 to 15 % of all invasive
breast tumors), represents the second most common
type of breast cancer after invasive ductal carcinoma
(IDC), otherwise referred as invasive carcinoma of no
special type [1, 2]. Recently, several evidences are
supporting the concept that ILC belongs to a distinct
family of breast disease with peculiar clinical and mo-
lecular characteristics [3, 4]. Indeed, ILC is more
commonly associated with older age at presentation,
larger tumor size and higher frequency of multifocality
and bilaterality compared with IDC [1, 5].
With regard to molecular features, the most frequent
genetic alteration of ILC is the loss of 16q chromosome,
where the E-cadherin gene (CDH1) is located [6]. The
loss of E-cadherin, a transmembrane glycoprotein that
mediates the adhesion between the epithelial cells,
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promotes invasion and metastatic behavior and is also
associated with the process of epithelial to mesenchymal
transition [5].
Invasive lobular breast cancer differs from IDC for
clinical outcome and recurrence pattern as well. It was
historically considered a good prognostic subtype, given
the more favorable pathological parameters (higher es-
trogen receptor [ER] expression, lower histological grade
and lower mitotic index in comparison with IDC) [7, 8].
However, more recent findings suggest that, despite a
trend towards slightly better short-term outcome, the
overall prognosis for patients with ILC seems to be
similar or worse than those with IDC, with a trend to
progressively relapse more frequently at approximately
6 years after the diagnosis [1, 9, 10].
Thus, the prognosis of ILC still remains controversial
and the definition of prognostic factors represents a
critical issue for clinical practice. Overall, the tumor
proliferation, measured by the immunohistochemical
assessment of Ki67 antigen, a nuclear protein expressed in
all cell-cycle phases other than G0, together with hormone
receptor and human epidermal growth factor receptor
2 (HER2) status, stage and histological grade, repre-
sent the main accepted prognostic factors for early
breast cancer [11].
Consistent data showed a statistically significant as-
sociation between Ki67 level and prognosis [12], but
the cut-offs to distinguish between ‘high’ and ‘low’
Ki67 varied from 14 to 29 %, also due to the continuous
distribution of the variable and to analytic and pre-
analytic barriers to standardized assessment. This
variability does not allow to easily compare the re-
sults of studies and to speculate about the reliance
and consistency between them [13].
As the majority of prognostic factors for early ILC, the
value of Ki67 derives from the context of trials where
the most of patients included are affected by IDC,
thereby limiting its clinical utility in the specific context
of ILC [14]. Thus, the long-term prognostic role of Ki67
in ILC has not yet been fully established.
The purpose of the current analysis was to investigate
the potential long-term impact of Ki67 assay and the
best prognostic cut-off value in a series of patients af-
fected by early stage ILC undergone surgical treatment.
Methods
Patients’ population
Clinical charts of consecutive patients affected by early
stage ILC undergone surgery at the University Hospital
of Verona, between January 1990 and December 2013
were considered eligible. Inclusion criteria were ‘pure’
or ‘mixed’ (ductal-lobular) ILC diagnosis (stage I-III),
curative surgery and availability of clinical-pathological
(age, Performance Status [PS], menopausal status, type of
surgery, clinical stage, treatments, grading, Ki67, ER, pro-
gesterone receptor [PgR], and HER2 status) parameters.
The study was approved by the local Ethics Committee
(Prot. CESC n° 24163, May 20th, 2014).
End-points
The aim of this analysis was to evaluate the impact of
Ki67 assay on disease free survival (DFS) and overall sur-
vival (OS), in order to identify the best prognostic cut-
off for patients with resected ILC. The DFS was defined
by the time between diagnosis and local or distant recur-
rence and OS was defined by the time between diagnosis
and death for any cause.
Immunohistochemical analyses
Immunohistochemistry was performed on surgical
specimens by automatic instrument (Bond, Menarini,
Florence) using 4 μm formalin-fixed paraffin-embedded
tissues and the following primary antibodies: Ki67 (MM1,
Novocastra, New Castle, UK, 1:50), ER (Rabbit SP1,
Thermo Sc. Labvision, Fremont, CA,1:50), PR (PgR 636,
Dako, Carpinteria, CA, 1:150), and HER2 (Hercept Test,
Dako, Milan). The immunohistochemical staining for
HER2 was scored according to Food and Drug Adminis-
tration criteria, and tumors with a 2+ staining were tested
for HER2 gene copy number by fluorescent in situ
hybridization (FISH, PathVysion, Abbott spa, Rome).
Statistics
Descriptive statistic was used to summarize pertinent
study information. Follow-up was analyzed and reported
according to Shuster [15]. The maximally selected
Log-Rank statistics analysis was applied to the Ki67
continuous variable in order to estimate the most appro-
priate cut-off values able to split patients into groups with
different DFS probabilities [16]. Associations between
variables and groups according to Ki67 were analyzed
(Chi-square test). The hazard ratio (HR) and the 95 %
Confidence interval (95 % CI) were estimated using the
Cox univariate model [17]. A multivariate proportional
hazard model was developed using stepwise regression
(forward selection, enter limit and remove limit, p = 0.10
and p = 0.15, respectively), to identify independent predic-
tors of outcomes in the whole population and in patients
with pure ILC (this subgroup analysis was specified a
priori). The Harrell’s guidelines for the identification of
the correct number of covariates were taken into account
for the power analysis (the number of events should have
be more than 10 times greater than the number of investi-
gated predictors, so that the expected error from the Cox
model would be less than 10 %) [18]. Survival was calcu-
lated by the Kaplan–Meier product limit method. The
log-rank test was used to assess differences between sub-
groups. Significance was defined at p < 0.05. The SPSS
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(18.0), R (2.6.1), and MedCalc (14.2.1) licensed statistical
programs were used for all analyses.
To address the multivariate model overfit and to valid-
ate the results, a cross-validation technique, which evalu-
ates the replication stability of the final Cox model in
predicting the outcomes, was also investigated [19–21].
This technique generates a number of simulation datasets
(at least 100, each approximately 80 % of the original size),
by randomly selecting patients from the original sample,
to establish the consistency of the model across less-
powered patient’ samples.
Finally, the Subpopulation Treatment Effect Pattern
Plot (STEPP) analysis was performed to assess the inter-
action between histological subtypes and Ki67; we aimed
to evaluate whether (and how much) the prognostic
effect (in terms of absolute DFS difference between
‘pure’ lobular and mixed ductal-lobular) varies according
to the Ki67 [22].
Results
Patients’ characteristics
Data from 405 patients with operable or locally ad-
vanced ILC, undergone surgery were gathered. Overall
patients’ characteristics are listed in Table 1. The median
patients age was 60 years (range 35–96 years), 115
(28.4 %) and 290 (71.6) were premenopausal and post-
menopausal, respectively. The majority of patients (379)
were ER positive (93.6 %) and PgR positive (335 patients,
82.7 %). With regard to the adjuvant treatment, hormo-
notherapy was administered to 85.4 % of patients, while
Table 1 Patients’ characteristics
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Legend – Table 1: ECOG Eastern Cooperative Oncology Group
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chemotherapy was administered in 39.3 %. Among
HER2-positive patients, 59.1 % of them received trastu-
zumab. One hundred-sixteen (28.6 %) recurrences and
86 (21.2 %) deaths did occur at a median follow-up of
67 months (range 1–396 months). Median DFS was
172 months (95 % CI 156–188), with a 5- and 10-year
rate of 80.4 and 67.8 %, respectively. Median OS was
225 months (95 % CI 200–250), with a 5- and 10-year
rate of 90.4 and 79.8 %, respectively.
Maximally selected log-rank statistics analysis
The optimal cut-off (absolute peak) in standardized Log-
Rank statistics plot was 6 %. This identified value allowed
to identify patients with a very good prognosis; thus, a fur-
ther maximally selected Log-Rank statistics analysis was
performed, by excluding patients with Ki67 < 6 %, in order
to better stratify the prognosis of ILC. According to this
analysis, the Ki67 cut point corresponds to 21 %. Patients
characteristics and their differences according to groups
identified by both cut-offs are reported in Table 2. These
cut-offs significantly correlated with both DFS (Fig. 1,
Table 2 Patients’ characteristics according to Ki67 groups
Patients’ characteristics Patients (%) p-value
Ki67 < 6 %
[N = 171]
6 % < Ki67
≤ 21 %
[N = 177]
Ki67 > 21 %
[N = 19]
Menopausal status
Premenopausal 50 (29.2) 47 (26.6) 9 (47.4) 0.16




0 163 (95.3) 162 (91.5) 18 (94.7)
1–2 8 (4.7) 15 (8.5) 1 (5.3)
Type of surgery
Conservative surgery 120 (70.2) 113 (63.8) 10 (52.6) 0.20
Mastectomy 51 (29.8) 64 (36.2) 9 (47.4)
Sentinel lymph-node
biopsy
No 92 (53.8) 105 (59.3) 14 (73.7) 0.20
Yes 79 (46.2) 72 (40.7) 5 (26.3)
Histological subtype
Pure lobular 119 (69.6) 129 (72.9) 12 (63.2) 0.72
Ductal-lobular 48 (28.1) 43 (24.3) 7 (36.8)
Others 4 (2.3) 5 (2.8) 0 (0)
T Descriptor according
to TNM [7° Edition]
1 115 (67.3) 93 (52.5) 6 (31.5) 0.01
2 43 (25.1) 60 (33.9) 11 (57.9)
3 11 (6.4) 17 (9.6) 1 (5.3)
4 2 (1.2) 7 (4.0) 1 (5.3)
Lymph-nodes status
Negative 111 (64.9) 92 (52.0) 10 (52.6) 0.06
Positive 56 (32.7) 74 (41.7) 9 (47.4)
Unknown 4 (2.3) 11 (6.2) 0 (0)
Estrogen receptor status
Negative 6 (3.5) 3 (1.7) 2 (10.5) 0.29
Positive 164 (95.9) 173 (97.7) 17 (89.5)
Unknown 1 (0.6) 1 (0.6) 0 (0)
Progesterone receptor
status
Negative 20 (11.7) 14 (7.9) 5 (26.3) 0.14
Positive 144 (84.2) 157 (88.7) 13 (68.4)
Unknown 7 (4.1) 6 (3.4) 1 (5.3)
HER2 status
Negative 124 (72.5) 118 (66.7) 11 (57.8) 0.01
Positive 4 (2.3) 12 (6.8) 4 (21.1)
Unknown 43 (25.1) 47 (26.6) 4 (21.1)
Table 2 Patients’ characteristics according to Ki67 groups
(Continued)
Histological grade
1 47 (27.5) 20 (11.3) 0 (0) <0.0001
2 57 (33.3) 87 (49.2) 9 (47.4)
3 15 (8.8) 33 (18.6) 6 (31.6)
Unknown 52 (30.4) 37 (20.9) 4 (21.1)
Vascular invasion
Absent 105 (61.4) 102 (57.6) 3 (15.8) <0.0001
Present 26 (15.2) 45 (25.4) 10 (52.6)
Unknown 40 (23.4) 30 (16.9) 6 (31.6)
Multifocality
Absent 131 (76.6) 137 (77.4) 16 (84.2) 0.48
Present 38 (22.2) 38 (21.5) 2 (10.5)
Unknown 2 (1.2) 2 (1.1) 1 (5.3)
Adjuvant
hormonotherapy
No 20 (11.7) 12 (6.8) 5 (26.3) 0.02
Yes 151 (88.3) 165 (93.2) 14 (73.7)
Adjuvant chemotherapy
No 111 (64.9) 102 (57.6) 1 (5.3) <0.0001
Yes 60 (34.1) 75 (42.4) 18 (94.7)
Adjuvant radiotherapy
No 48 (28.1) 54 (30.5) 8 (42.1) 0.48
Yes 118 (69.0) 114 (64.4) 11 (57.9)
Unknown 5 (2.9) 9 (5.1) 0 (0)
Legend – Table 2: N number, p-value chi-square test, ECOG Eastern Cooperative
Oncology Group
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Panel a) and OS (Fig. 1, Panel b); outcomes according to
Ki67 cut-offs of 6 % or 21 % are shown in Additional file 1:
Figure S1. In order to further enhance the usefulness of the
analysis and to generate implications for clinical practice,
the DFS and OS according to Ki67 in the context of pa-
tients with ER positive and HER2-negative disease is
shown Fig. 2. With the same principle and for clinical
speculation, DFS and OS according to Ki67 and nodal in-
volvement are shown in Additional file 2: Figure S2.
Multivariate analysis
At the multivariate analysis, Ki67, negative lymph-node
status and adjuvant radiotherapy were significant inde-
pendent predictors for longer DFS. With regard to OS,
Ki67, negative lymph-node status, and age <60 years
were significant prognostic predictors (Table 3). With re-
gard to the 290 patients with pure ILC, Ki67 (HR 4.04,
95 % CI 1.82–8.98, p = 0.001), and negative lymph-node
status (HR 3.45, 95 % CI 2.08–5.72, p < 0.001) were signifi-
cant independent predictors for longer DFS. With regard
to OS, Ki67 (HR 3.92, 95 % CI 1.55–9.94, p = 0.004),
negative lymph-node status (HR 3.55, 95 % CI 1.90–6.63,
p < 0.001), and age <60 years (HR 2.51, 95 % CI 1.35–4.67,
p = 0.004) were significant prognostic predictors. Survival
curves according to Ki67 for pure ILC patients are shown
in Fig. 1, Panels c-d.
Internal validation analysis
At the internal cross-validation analysis, Ki67, lymph-
node status and radiotherapy were confirmed as inde-
pendent factors for DFS (replication rate: 85, 100, and
55 %, respectively) and Ki67, lymph-node status, and
age, for OS (replication rate: 100, 98, and 96 %).
STEPP analysis
The STEPP analysis shows a trend towards significant
interaction according to histology (‘pure’ ILC versus
mixed ductal-lobular ILC) in terms of both 5-years DFS
differences (Fig. 3, Panel a) and absolute rates (Fig. 3,
Panel b) when increasing Ki67 positivity (p = 0.03). Indeed,
Fig. 1 Disease-Free Survival (DFS) [Panel a and c] and Overall Survival (OS) [Panel b and d] according to Ki67, for patients with invasive lobular
carcinoma (ILC) [Panels a and b] and patients with pure ILC [Panels c and d]; p-value: log-rank analysis
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with high value of Ki67 patients with pure ILC show to
perform worse than mixed histology in terms of DFS.
Discussion
The results of the analysis reported herein suggest that
the Ki67 assay is able to significantly discriminate the
long-term prognosis of patients with primary resected
ILC. Indeed, Ki67 emerges as a significant prognostic
factor in multivariate analysis and the best cut-offs able
to discriminate between very ‘good prognosis’ and ‘poor
prognosis’ seems to be 6 and 21 %. If ‘very good performers’
(i.e. very low proliferation, Ki67 < 6 %) are excluded, the
cut-off of 21 % is confirmed (and internal validated) as an
independent predictor for longer DFS and OS.
The prognostic significance of Ki67, a well-established
cell proliferation marker in cancer, have been extensively
investigated in studies mainly conducted in IDC cases in
order to provide early and accurate information upon
both outcome and prediction of response to treatment.
These studies have shown an independent significant as-
sociation between high Ki67 expression and increased
risk of breast cancer relapse and benefit of the addition
of adjuvant cytotoxic chemotherapy [23, 24]. Thus,
immunohistochemical Ki67 assay, together with ER,
PgR and HER2 status, was chosen as a useful and
easily-to-apply surrogate for gene expression profile to
defined breast cancer molecular subtypes, despite a
lesser analytical validity than molecular testing and a
reliable clinical validation. This step represents a crucial
issue for treatment decision of early breast cancer given
that molecular subtypes support physicians in daily
clinical practice.
Proliferation is a key process for breast cancer devel-
opment, and these genes are among the most repre-
sented in the context of the currently validated genomic
tests (ex. Oncotype Dx), which have been developed to
assess the risk of recurrence and identify those patients
who are most likely to benefit from chemotherapy
[25, 26]. Although a standardized cut-off for Ki67 have
not been established as the search for Ki67 cut-offs is un-
reliable and the assessment for Ki67 has very wide inter-
laboratory variation [27], a threshold within the range of
20–29 % was considered indicative of high Ki67 status
[11]. These evidences almost exclusively derived from
patients with IDC, and these implications are applied
in clinical practice for ILC patients as well.
Fig. 2 Disease-Free Survival (DFS) [Panel a] and Overall Survival (OS) [Panel b] according to Ki67, for patients with estrogen receptor positive/
HER2-negative invasive lobular carcinoma (ILC); p-value: log-rank analysis
Table 3 Multivariate analysis
Disease-free survival Overall survival
Variables HR 95 % CI p-value HR 95 % CI p-value
Lymph-node status (Positive vs negative) 4.57 2.14–9.75 <0.0001 5.38 2.26–12.79 <0.0001
Ki67 (>21 % vs ≤21 %) 3.61 1.35–9.63 0.010 12.58 4.13–38.23 <0.0001
Radiotherapy (No vs Yes) 2.72 1.10–4.66 0.026 2.1 0.89–4.91 0.087
Age (>60 year vs ≤60 year) - - - 3.74 1.53–9.13 0.004
Legend – Table 3: HR Hazard Ratio, CI confidence intervals, vs versus, yrs years
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Fig. 3 Subpopulation Treatment Effect Pattern Plot (STEPP) Analysis of Ki67 assay according to histology: Prognostic Relevance for resected early
stage pure and mixed invasive lobular carcinoma (ILC); Panel a: differences in Disease-Free Survival (DFS) rates at 60 months, between patients
with pure and mixed (ductal-lobular) ILC according to patients’ subpopulations clustered by Ki67 (%) [the solid line above 0 on the y-axis indicates
better DFS at 60 months for mixed ILC compared with pure ILC as values of Ki67 increase from left to right on the x-axis]; Panel b: DFS rates at
60 months of patients with pure and mixed ILC according to patients’ subpopulations clustered by Ki67 (%)
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To our knowledge, no previous study clearly demon-
strated a significant prognostic effect of Ki67 on DFS or
OS in the featured context of early ILC. Indeed, a study
conducted in a large series of ‘pure’ ILC cases adopting
a pre-determined Ki67 cut-off of 20 % demonstrated no
independently significant prognostic role of Ki67 on
prognosis [28]. Similarly, in another retrospective study
the Ki67 value was a significant prognostic factor in uni-
variate analysis, but did not reach significance after ad-
justment for others known prognostic factors [29].
With regard to histology, the multivariate analysis con-
firms that a high Ki67 (>21 %) is associated with poor
prognosis, and the STEPP analysis suggests an inter-
action against ‘pure’ ILC, which display to have a worse
prognosis in comparison with mixed ductal-lobular, as
the Ki67 positivity increases. The aggressive biological
behavior of high Ki67 ILC is also corroborated by the
significant association between high Ki67 and other po-
tential prognostic predictors in breast cancer, such as
tumor size, lymph-node status, HER2 status, vascular in-
vasion and histological grade (Table 2). However, only
lymph-node status represents a significant independent
predictor for survival at the multivariate analysis.
In the context of ILC, the magnitude of the benefit of
the addition of chemotherapy to hormonal therapy rep-
resents an open question, in particular for the absence
of prospective randomized trials [30]. In our study, the
unfavorable prognostic trend of patients with high Ki67
is not counteracted by the adjuvant chemotherapy re-
ceived by almost all these patients. However, the small
sample size would not easily allow to detect the potential
advantage of the addition of adjuvant chemotherapy to
hormonal therapy in patients with hormone receptor
positive and HER2 negative disease, considering that
even in the best scenario of predominance of IDC this
benefit is around 4 % [31].
Based on the STEPP analysis, the prognostic impact of
high Ki67 on 5-year DFS is primarily driven by the very
poor outcome of ‘pure’ ILC patients with highest levels
of Ki67. The few number of these patients represents
one of the crucial limitation of our study that allow
only to generate a hypothesis concerning the prognostic
role of Ki67 in ILC. These data open further perspec-
tives for such histology, and deserve to be confirmed in
larger series.
Conclusion
Despite the retrospective and exploratory nature of the
study, the different types and duration of adjuvant treat-
ments, the absence of a central pathology review, our
study indicates that Ki67 is able to significantly discrim-
inate the prognosis of patients with ILC, and this effect
is more pronounced for patients with pure ILC. In par-
ticular, if we derive suggestions for additional studies in
the context of local laboratory values, the prognostic
analysis of ILC according to Ki67 is able to identify
patients with a low-proliferative tumor (Ki67 < 6 %, in
general less than 5 %) and patients with a ‘true’ high-
proliferative tumors (Ki67 > 21 %, higher than 20 %). It
is important to emphasize that patients with a Ki67 of
21 % or higher represent a small sample size (about 5 %)
of our whole ILC population. This data, although it is in
line with previous studies that demonstrate the low
mitotic index characterizing the most of LBC subtype,
contributes to not draw any definitive conclusions and
to not consider a Ki67 value of 21 % as an absolute cut-
off. Moreover, the limited role of these cut-offs are also
determined by the absence of standard Ki67 assess-
ments’ methodology. Our results suggest to pay particu-
lar attention to those few LBC patients with a high Ki67
value as their prognosis could be closely affected by the
high mitotic index. Certainly, all these results need to be
validated in further studies before that the cut-offs can
be used clinically. Moreover, studies including gene ex-
pression profiles are needed as well in order to clarify
the biologic features of ILC.
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